Delivery Order SPE2DB20D2104-SPE2DB25FMZZL
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Jatenzo 198 mg capsules (120-count units) valued at $1,131.88 under a firm fixed-price contract. This is a non-set-aside competitive award with an ultimate completion date of August 13, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $3,988.39 to AmerisourceBergen Drug Corp for 120 capsules of Jatenzo 237 mg on September 9, 2025, with completion scheduled for September 10, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $5,877.30 to AmerisourceBergen Drug Corp for 120 capsules of Jatenzo 237 mg on August 20, 2025, with completion scheduled for August 21, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order from its corporate office location....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a ceiling value of $1,226.39. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. No set-aside designation was used in this competitive award. The product...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Jatenzo 158 mg capsules (120-count unit) under a firm fixed-price contract with a ceiling value of $1,983.45. The award, made on September 8, 2025, is a non-set-aside competitive award with an ultimate completion date of September 9, 2025. This delivery order is executed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Jatenzo 198 mg capsules (120 count) with a ceiling value of $1,244.80 and firm fixed pricing. This non-competitive delivery order is expected to be completed by September 15, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal...
- The Defense Logistics Agency awarded a $8,442.15 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Jatenzo 237 mg capsules (120-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 24, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, reflecting the company's role as a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Jatenzo 237 mg capsules (120 count) at a ceiling value of $2,263.74. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award to the vendor. The ultimate completion date is set for August 19, 2025, with performance originating from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,283.72 to AmerisourceBergen Drug Corp for Jatenzo 237 mg capsules (120-count supply) on September 9, 2025, with completion scheduled for September 10, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $1,094.07 firm fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of JATENZO 237 MG CAPSULE 120S, a pharmaceutical product, with a period of performance through November 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMZZLDelivery Order
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a ceiling value of $1,636.67. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The delivery order is scheduled for completion by September 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, is a critical vendor for federal medical procurement serving military and veteran healthcare systems. The company's DLA prime vendor contract enables it to supply a comprehensive portfolio of pharmaceutical products and medical supplies—including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains—to support military healthcare programs worldwide. This specific delivery order for Jatenzo, a testosterone replacement therapy medication, exemplifies the company's role in fulfilling pharmaceutical supply needs for the Defense Health Agency and other government healthcare systems through competitively awarded contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 9/10/25 |